Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FK01 is a preclinical-stage live biotherapeutic product (LBP) being developed by Zhiyi Biotechnology for the treatment of bacterial vaginitis. As an LBP, it is designed to modulate the local vaginal microbiome, likely by restoring a healthy balance of microflora and inhibiting the overgrowth of pathogenic bacteria associated with the condition. The program is currently in the preclinical phase of development and represents part of Zhiyi Biotech's broader focus on microbiome-based therapeutics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FK01.